"","Num","POD","SD","%","Genes","KE"
"GO:0009653","2","0.00151929429145508","0.0355303503258077","40","foxa1, foxa2","INCREASED DEVELOPMENTAL DEFECTS"
"VENTRICULAR ARRHYTHMIA","2","0.00160808258078526","0.0196059831393007","28.57","bmp2a, raf1b","OCCURRENCE CARDIAC ARRHYTHMIA"
"GO:0008015","2","0.00161809214487062","0.0951730190300429","66.67","gli2a, tnnt2a","INSUFFICIENCY VASCULAR"
"ABNORMALITY OF THE WING OF THE ILIUM","2","0.00183007809975859","0.0302754495616747","33.33","hdac6, sec23a","INCREASED DEFORMED WING VIRUS LEVELS"
"ABNORMAL PROLACTIN LEVEL","3","0.0130475293360537","0.556249607702314","37.5","foxa2, gli2a, pik3ca","DECREASED PROLACTIN"
"ABNORMAL HYPOTHALAMUS PHYSIOLOGY","3","0.0132521904249797","0.554470832258517","33.33","fgf8a, gli2a, pik3ca","REDUCED PROSTAGLANDIN E2 CONCENTRATION HYPOTHALAMUS; DECREASE E2 BLOOD CONCENTRATIONS AT HYPOTHALAMUS"
"ANTERIOR PITUITARY AGENESIS","3","0.0138784946939568","0.571713948007191","60","foxa2, gata6, gli2a","INCREASED SECRETION OF LH FROM ANTERIOR PITUITARY"
"REGULATION OF ATPASE ACTIVITY","3","0.0151219310042571","0.549566343469141","18.75","atp1b3b, gtf2h4, tnnt2a","INHIBITION CA++ ATPASE"
"ABNORMAL PLEURA MORPHOLOGY","3","0.0284247765066487","0.567492536521845","37.5","bmp2a, calcrla, ccnd1","PERSISTENT CYTOTOXICITY PLEURA OR PERITONEUM"
"IMMUNOLOGIC HYPERSENSITIVITY","4","0.0301543153907288","0.38535409690015","17.39","fgf8a, gli2a, ptger2a, rbm8a","INCREASE ALLERGIC RESPIRATORY HYPERSENSITIVITY RESPONSE"
"GO:0005125","4","0.031795319369277","0.508392093845407","16","bmp1a, bmp2a, inhbb, wnt1","ACTIVATION INFLAMMATORY CYTOKINES CHEMOKINES CYTOPROTECTIVE GENE PATHWAYS"
"G TGF BETA SIGNALING PATHWAY","7","0.0323415548920595","0.246570666956034","10.29","bmp2a, id1, inhbb, myca, mycb, rps6kb1b, tfdp1a","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"NEUROINFLAMMATION","2","0.0361698623261484","1.0319182053315","16.67","chuk, jun","N/A NEUROINFLAMMATION"
"GO:0030545","6","0.0381775750664335","0.306534290990213","10.17","bmp1a, bmp2a, fgf8a, inhbb, nppa, wnt1","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"DECREASED PLASMA CARNITINE","2","0.0420000676974904","1.08576859216194","28.57","acadm, dldh","REDUCTION PLASMA VITELLOGENIN CONCENTRATIONS; INCREASE PLASMA VITELLOGENIN CONCENTRATIONS; DECREASED RENAL PLASMA FLOW; INCREASED PLASMA TYROSINE; DECREASED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"GO:0004738","2","0.0420416516114751","1.08607249151802","50","dldh, pdhx","INCREASED INDUCTION OF PYRUVATE DEHYDROGENASE PDH; INHIBITION PYRUVATE DEHYDROGENASE KINASE PDK ENZYME"
"HEPATOCELLULAR CARCINOMA","2","0.0433671895368131","0.992159826914247","15.38","bmp2a, pik3ca","FORMATION HEPATOCELLULAR AND BILE DUCT TUMORS; INCREASE ADENOMAS/CARCINOMAS HEPATOCELLULAR; TUMORIGENESIS HEPATOCELLULAR CARCINOMA"
"SANDAL GAP","2","0.0433671895368131","0.992159826914247","40","bmp2a, pik3ca","N/A GAP"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","2","0.0442820139092977","0.985749136076004","15.38","fgf8a, pik3ca","INCREASED IGF-1 MOUSE"
"GO:0030520","2","0.0517790215722427","1.11917993083322","25","ar, foxa1","ACTIVATION ESTROGEN RECEPTOR ALPHA"
"HYPERACTIVITY","6","0.0530061697718078","0.283848680528808","12","fgf8a, gli2a, glud1a, pik3ca, pola1, tmco1","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"GO:0007249","6","0.0548890347534186","0.232325229402453","13.95","chuk, cth, hmox1a, roraa, ube2ia, wls","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"GO:0010463","2","0.0567400044781055","1.07469904924961","16.67","bmp2a, mycb","INCREASED PROLIFERATION OF MESENCHYMAL CELLS"
"GO:0045444","10","0.0568142291745075","0.157791155115301","24.39","bmp2a, ccnd1, egr2b, hdac6, inhbb, per2, ppardb, roraa, tph1b, wnt1","INCREASED ADIPOGENESIS"
"DECREASED FERTILITY","8","0.0587866537844715","0.213162663535744","10.53","ar, cyb5a, fgf8a, foxa2, gli2a, nup107, polr3h, raf1b","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"RESPONSE TO REACTIVE OXYGEN SPECIES","8","0.0594746129619285","0.165807337903986","14.29","chuk, cyp1b1, fyna, hdac6, hmox1a, jun, sod1, stk25b","INCREASED REACTIVE OXYGEN SPECIES"
"GO:0099536","8","0.0648939913494629","0.19888580056061","7.21","egr2b, ephb2b, gad2, gsk3b, pcdh17, rap1b, raraa, rpl22","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"HEART DEVELOPMENT","20","0.0662670183311077","0.0713900896237869","15.87","bmp2a, calcrla, cdc42, ddx39b, ednraa, fgf8a, foxa2, gata5, gata6, gli1, gli2a, mthfd1b, nppa, parp2, pparab, ppardb, raf1b, raraa, tek, tnnt2a","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"GO:0005102","17","0.0666675938169782","0.0922899386945622","8.17","ar, bmp1a, bmp2a, cdc42, eif3s10, ephb2b, fgf8a, hsp90b1, inhbb, ncoa4, nppa, ran, raraa, rxraa, wls, wnt1, yars","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"GO:1903008","3","0.068437851873711","0.444088887651992","23.08","hdac6, pelo, tspo","DISRUPTION LYSOSOME"
"ABNORMAL NASAL MORPHOLOGY","29","0.0748129803750827","0.0490013654571496","18.71","bmp2a, bub3, cdc42, ednraa, fgf8a, gata5, gata6, gli2a, hdac6, impdh1b, kif1bp, naga, pex19, pik3ca, raf1b, raraa, rbm8a, rpl15, rpl27, rpl31, rpl35a, RPS17, rps19, rps23, rps24, rps29, sec23a, tmco1, umps","INCREASE SITE OF CONTACT NASAL TUMORS"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","7","0.0782692088453453","0.23124927202676","6.86","ar, foxa1, hdac6, ncoa4, pparab, ppardb, rxraa","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"MORTALITY AGING","5","0.0801265251068213","0.258365201568986","19.23","calcrla, hdac6, pex19, pik3ca, rbm8a","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"GO:0009790","26","0.0855346036934332","0.0527585660384179","15.38","apaf1, ar, bmp2a, dldh, ednraa, ephb2b, fgf8a, foxa1, foxa2, gata6, gli1, gli2a, hoxb3a, kif1bp, krt8, krt94, mthfd1b, pax5, pelo, prp19, raraa, rdh10a, rxraa, sod1, wls, wnt1","DEFECT OF EMBRYOGENESIS"
"PEPTIDYL LYSINE MODIFICATION","10","0.0855534105895754","0.152703641656085","14.08","cth, egr2b, hdac6, nup107, nup85, pax5, pom121, pwp1, ruvbl1, ube2ia","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0042701","3","0.0856176460049636","0.51213900695128","8.82","cdc23, pik3ca, raf1b","DECREASED PROGESTERONE FROM CORPUS LUTEUM"
"NEGATIVE REGULATION OF FAT CELL PROLIFERATION","2","0.0866455083671146","0.653656649542672","50","per2, tfdp1a","INDUCTION SUSTAINED CELL PROLIFERATION"
"GO:0001935","4","0.0957337582115477","0.312872129780906","11.11","bmp2a, hmox1a, jun, tek","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"GO:0048813","6","0.0992631441696182","0.234377680853672","46.15","cdc42, ephb2b, gsk3b, hdac6, id1, stk11","ABERRANT DENDRITIC MORPHOLOGY"
"GO:0006633","3","0.101048171135671","0.51364274300528","10.34","cyp1a, eif6, prkag1","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","8","0.10545152804851","0.198532723868897","44.44","rpl15, rpl27, rpl31, rpl35a, RPS17, rps19, rps24, rps29","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","8","0.10545152804851","0.198532723868897","40","rpl15, rpl27, rpl31, rpl35a, RPS17, rps19, rps24, rps29","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"GO:0043542","5","0.109939953042613","0.22434696548719","14.29","cyp1b1, hmox1a, id1, pik3ca, tek","INCREASED MIGRATION ENDOTHELIAL CELLS"
"RESPONSE TO ESTRADIOL","3","0.110174934497818","0.567556852532584","10","ccnd1, cyp1a, foxa1","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"GO:0006412","25","0.115149162052091","0.0586361602731503","23.15","eif2b4, eif3d, eif3s10, eif4e2rs1, eif4ea, eif6, rpl14, rpl15, rpl18a, rpl19, rpl22, rpl23a, rpl24, rpl27, rpl31, rpl35a, rpl5b, RPS17, rps19, rps21, rps23, rps24, rps29, rsl24d1, yars","ALTERED PROTEIN PRODUCTION"
"ABNORMAL CIRCULATING FATTY ACID CONCENTRATION","3","0.116537713408272","0.572238244351613","33.33","acadm, dldh, pex19","ACCUMULATION FATTY ACID"
"GO:0040011","25","0.117373281070842","0.0517904948065921","11.01","bmp2a, cdc42, cyp1b1, egr2b, ephb2b, fgf8a, gli2a, hdac6, hmox1a, id1, igfbp5b, jun, krt8, nup85, pik3ca, plp2, ppardb, ptpn6, raf1b, rpl24, rps19, rps6kb1b, sox1b, tek, tspo","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"GO:0001816","16","0.118334942447968","0.0843969586877804","13.33","chuk, cyp1b1, gata6, hmox1a, inhbb, mapkapk2a, mre11a, nploc4, polr3b, polr3d, polr3h, ptpn6, raraa, roraa, sod1, tspo","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"GO:0004872","20","0.121361184705373","0.0691557593346932","8.37","ar, bmp2a, calcrla, ednraa, ephb2b, fgf8a, inhbb, nppa, paqr3a, pparaa, pparab, ppardb, ptger2a, raraa, roraa, rorab, rxraa, tacr1b, tek, wnt1","ACTIVATION PXR/SXR"
"CYTOPLASMIC RIBOSOMAL PROTEINS","17","0.125625800784223","0.0884404824666042","11.81","rpl14, rpl15, rpl18a, rpl19, rpl22, rpl23a, rpl24, rpl27, rpl31, rpl35a, RPS17, rps19, rps21, rps23, rps24, rps29, rps6kb1b","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"GO:0042060","11","0.127960307365521","0.118419571092393","12.5","cdc42, foxa2, gata5, gata6, hmox1a, pik3ca, pkma, pparab, ppardb, ptpn6, raf1b","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0016055","3","0.128283762284677","0.553453340084438","13.04","csnk1da, wls, wnt1","ALTERATION WNT PATHWAY"
"GO:0044703","19","0.128571764638191","0.0820355087267182","16.38","ar, cyp1a, dldh, gli1, igfbp5b, inhbb, nppa, pafah1b3, pax5, ppardb, prkag1, raraa, rps6kb1b, ruvbl1, rxraa, sod1, stk11, umps, vdac2","N/A REPRODUCTIVE FAILURE"
"GO:0006120","3","0.130417729478758","0.585317737662736","11.11","dldh, ndufa5, ndufb5","BINDING OF INHIBITOR NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"GO:0046903","27","0.132783245521987","0.0511991935453205","11.69","apaf1, ccnd1, chuk, cyb5r3, foxa2, gad2, glud1a, gsk3b, hmox1a, impdh1b, inhbb, llgl2, nppa, pa2g4b, pdia4, per2, pkma, ppardb, psmd6, psmd9, ptpn6, raf1b, rap1b, slc25a5, sod1, umps, wls","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"GO:0042446","4","0.134207062850323","0.316576112964192","14.29","bmp2a, fdx1, hsd11b1la, tspo","INCREASE LUTEINIZING HORMONE LH; REPRESSED EXPRESSION OF STEROIDOGENIC ENZYMES"
"GO:0048870","20","0.135260092571759","0.0628301937079379","10","bmp2a, cdc42, cyp1b1, fgf8a, hdac6, hmox1a, id1, igfbp5b, jun, krt8, nup85, pik3ca, ppardb, ptpn6, raf1b, rps19, rps6kb1b, sox1b, tek, tspo","INCREASED MOTILITY"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","16","0.137374678700065","0.0972897127145659","15.53","ar, bmp2a, cyb5a, eif2b4, fgf8a, foxa2, gli2a, impdh1b, mre11a, nup107, pik3ca, pola1, polr3b, polr3h, raf1b, raraa","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"GO:0006936","9","0.139889112823793","0.149194097742811","16.36","calcrla, chuk, ednraa, nppa, pik3ca, rps6kb1b, sod1, tnnt2a, tpm3","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"POSITIVE REGULATION OF GENE EXPRESSION","28","0.152119708043152","0.0469843261330946","15.47","ar, bmp2a, chuk, cyp1b1, ddx39b, eif3d, eif6, ephb2b, fgf8a, gata5, gata6, gsk3b, hmox1a, id1, mapkapk2a, mre11a, myca, mycb, pkma, polr3b, polr3d, polr3h, prkag1, prp19, raraa, roraa, rps6kb1b, sod1","ALTERED GENE EXPRESSION"
"GO:0000003","34","0.154939614328603","0.0435122695329586","16.75","ar, bub3, ccnd1, cyp1a, dldh, eif2b4, fgf8a, foxa1, gata6, gli1, gli2a, igfbp5b, inhbb, krt8, krt94, mre11a, ncoa4, nppa, nup107, pafah1b3, pax5, ppardb, prkag1, raraa, rdh10a, rps6kb1b, rrm1, ruvbl1, rxraa, sod1, stk11, umps, vdac2, zw10","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"ABNORMAL LUNG MORPHOLOGY","22","0.157507503848562","0.0658489305139286","17.19","bmp2a, bub3, calcrla, ccnd1, cdc42, farsb, fgf8a, gata6, gli1, gli2a, mcm4, mthfd1b, nhp2, nup107, pola1, polr3h, raf1b, raraa, stk11, tnnt2a, tpm3, umps","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"GO:0016310","14","0.163402922243004","0.0957155722684828","11.2","chuk, csnk1da, ephb2b, fyna, gsk3b, mapkapk2a, pik3ca, pkma, prkag1, raf1b, rps6kb1b, stk11, stk25b, tek","ACTIVATION SP1"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","23","0.170566415389484","0.0619590709792345","15.65","bmp2a, bub3, calcrla, ccnd1, cdc42, farsb, fgf8a, gata6, gli1, gli2a, mcm4, mthfd1b, nhp2, nup107, pola1, polr3h, raf1b, raraa, sod1, stk11, tnnt2a, tpm3, umps","INCREASED RESPIRATORY DISTRESS/ARREST"
"GO:0007568","11","0.171420215930645","0.120448952649026","12.79","apaf1, cyp1a, dldh, igfbp5b, jun, pax5, rpn2, rps6kb1b, sod1, tspo, wnt1","ACCELERATED AGING"
"GO:0019882","6","0.174009095742777","0.269231441858986","10.17","chuk, psmb3, psmb5, psmd6, psmd9, sec23a","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"GO:0046983","29","0.176354309310594","0.048211811324637","14.72","acat1, adh5, ar, atf1, atf6, bmp2a, chuk, gad2, gale, hmox1a, id1, inhbb, jun, mycb, naga, nfs1, pafah1b3, pola2, pole4, polr2j, prmt5, raf1b, ran, raraa, rps19, rxraa, sod1, stk25b, tfdp1a","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"ABNORMAL LIVER MORPHOLOGY","18","0.18107131782925","0.0704268147606501","15.13","acadm, acat1, bmp2a, dldh, farsb, gale, hmox1a, krt8, mcm4, naga, nhp2, pccb, pex19, pik3ca, raf1b, rbm8a, sdha, tnnt2a","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"REGULATION OF CELL DEATH","40","0.184032037989543","0.0334079026446169","14.93","apaf1, ar, atf6, bmp2a, cdc42, ciapin1, cth, ctnnbl1, cyp1b1, fgf8a, foxa1, fyna, gata6, gli2a, gsk3b, hdac3, hdac6, hmox1a, hsp90b1, id1, inhbb, jun, mre11a, myca, mycb, pa2g4b, parp2, pik3ca, pparab, ppardb, ptpn6, raf1b, raraa, rps6kb1b, slc25a5, sod1, tek, tspo, vdac2, wnt1","N/A CELL INJURY/DEATH"
"GO:0030154","12","0.185344951785741","0.110704807261644","18.46","foxa1, foxa2, fyna, hs6st2, kif1bp, pparaa, pparab, ppardb, raraa, rxraa, sox1b, wnt1","DIFFERENTIATION OF MYOFIBROBLAST"
"GO:0006839","8","0.189047795359844","0.147398744843119","17.39","atp5f1, gsk3b, hspa4b, kif1bp, slc25a5, tfdp1a, tomm34, tspo","REDUCTION CHOLESTEROL TRANSPORT IN MITOCHONDRIA"
"ABNORMAL FORM OF THE VERTEBRAL BODIES","6","0.196273003410299","0.262573421212179","18.18","bmp1a, hdac6, rps19, sec23a, tmco1, wnt1","CLONAL EXPANSION/CELL PROLIFERATION TO FORM ALTERED HEPATIC FOCI AHF"
"GO:0009611","19","0.20085307312228","0.0686936628046948","16.96","cdc42, cyp1a, foxa2, gata5, gata6, gli1, hmox1a, inhbb, jun, pik3ca, pkma, pparab, ppardb, ptpn6, raf1b, rps6kb1b, sod1, tspo, wnt1","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"DECREASED BODY WEIGHT","32","0.207627958054597","0.0405907551018303","14.16","acadm, acat1, bmp1a, ccnd1, cyb5a, cyb5r3, dldh, farsb, fgf8a, gale, gata6, gli1, gli2a, krt94, pccb, pdhx, pex19, pik3ca, pola1, raraa, rpl15, rpl27, rpl31, rpl35a, RPS17, rps19, rps24, rps29, sdha, sdhb, tpm3, umps","DECREASED BODY WEIGHT"
"REGULATION OF WNT SIGNALING PATHWAY","10","0.209489592390936","0.145483613806168","12.66","bmp2a, gli1, gsk3b, psmb3, psmb5, psmd6, psmd9, ruvbl1, stk11, wls","INHIBITION WNT PATHWAY"
"SIGNALING OF HEPATOCYTE GROWTH FACTOR RECEPTOR","4","0.221387710615077","0.361357203041616","11.76","jun, pik3ca, raf1b, rap1b","OCCURRENCE CYTOPLASMIC VACUOLIZATION HEPATOCYTE; OCCURRENCE BALLOONING DEGENERATION HEPATOCYTE"
"GO:0072358","17","0.22342338590533","0.0619229609411948","15.32","calcrla, cdc42, cth, cyp1b1, ednraa, ephb2b, fgf8a, gata6, hmox1a, hoxb3a, id1, jun, pik3ca, pkma, roraa, stk11, tek","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"GO:0004620","2","0.224837368298127","0.293707895164185","40","ednraa, hmox1a","INHIBITION PHOSPHOLIPASE A"
"GO:0006954","14","0.226144629368414","0.085787079426611","11.97","bmp2a, calcrla, chuk, hmox1a, jun, mapkapk2a, nppa, pparab, ppardb, ptger2a, roraa, rps19, sod1, tek","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"ABNORMALITY OF THE BLADDER","8","0.238538843565523","0.1673137117613","15.38","ccnd1, glud1a, hs6st2, pik3ca, raraa, sdha, sdhb, stk11","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"GO:0005515","7","0.239730740502869","0.209933854628303","14.89","bmp1a, cdc42, chuk, eif4ea, gata5, gli1, ran","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"ABNORMALITY OF THE ABDOMINAL ORGANS","28","0.242740577152578","0.043184562775034","16.57","acadm, acat1, bmp2a, ccnd1, dldh, farsb, gale, gata6, hmox1a, hsd17b10, krt8, mcm4, mre11a, myca, mycb, naga, nhp2, pccb, pex19, pik3ca, raf1b, raraa, rbm8a, sdha, sdhb, stk11, tnnt2a, umps","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"REGULATION OF PROTEOLYSIS","8","0.242993610017622","0.166128235417648","7.14","apaf1, fyna, gsk3b, hdac6, myca, mycb, raf1b, wnt1","IMPAIRED PROTEOSTASIS"
"GO:0019904","20","0.247487013563014","0.0637795543920442","16.26","ar, cdc42, egr2b, foxa1, foxa2, gng12a, jun, llgl2, polr2j, pparab, ptpn6, raraa, rps6kb1b, rrm1, rxraa, srp72, stk11, tfdp1a, ube2ia, wnt1","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"PYRUVATE METABOLIC PROCESS","9","0.251353159968372","0.153747709537869","16.07","dldh, eif6, nup107, nup85, pdhx, pkma, pom121, pparab, prkag1","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"CHOLESTASIS","4","0.259606723990302","0.242213408682272","11.43","farsb, gale, krt8, pex19","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"GO:0005488","149","0.261688090510916","0.00842910126232515","13.85","acadm, acat1, adh5, apaf1, ar, atf1, atf6, bmp1a, bmp2a, bub3, cdc42, cdc42l, cfl1l, chpt1, chuk, ciapin1, csnk1da, cth, cul1a, cyb5a, cyb5r3, cyp1a, cyp1b1, cyp2aa3, dao.1, ddx39b, dldh, egr2b, EIF1B, eif2b4, eif3d, eif3s10, eif4e2rs1, eif4ea, eif6, ephb2b, exosc7, farsb, fdx1, fgf8a, foxa1, foxa2, fyna, gad2, gata5, gata6, gli1, gli2a, gng12a, gsk3b, gtf2h4, hdac3, hdac6, hmgcrb, hmox1a, hoxb3a, hsp90b1, htatsf1, id1, igfbp1a, igfbp5b, impdh1b, inhbb, jun, lig3, llgl2, mapkapk2a, mcm4, mitfa, mmp17b, mre11a, mthfd1b, myca, mycb, nars, nfs1, nhp2, nploc4, nppa, pa2g4b, parp2, pax5, pcdh17, pelo, per2, pes, pex19, pik3ca, pkma, pola1, pola2, pole4, polr2i, polr2j, polr3b, polr3d, polr3h, pom121, pop7, pparaa, pparab, ppardb, prkag1, raf1b, ran, rap1b, raraa, rbm8a, rnf7, roraa, rorab, rpa3, rpl14, rpl15, rpl19, rpl22, rpl24, rpl5b, rps19, rps29, rps6kb1b, rrm1, rsl24d1, ruvbl1, rxraa, sdha, sdhb, sec23a, sf3b3, smx5, snrpg, sod1, sox1b, srp72, srsf3b, stk11, stk25b, tek, tfdp1a, tnnt2a, tomm34, tph1b, tpm3, ube2ia, vdac2, wls, wnt1, yars, zgc-55733","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"ABNORMALITY OF THE MITOCHONDRION","5","0.266373058005421","0.264182554338792","3.97","acadm, dldh, hsd17b10, pdhx, sdha","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"GO:0001525","8","0.267723571640093","0.150059673543293","21.62","calcrla, gsk3b, hdac3, hdac6, hs6st2, rps29, tek, wdr43","REDUCTION ANGIOGENESIS; INCREASED ANGIOGENESIS"
"ABNORMALITY OF THE PITUITARY GLAND","11","0.2799308892851","0.133210780435165","22.92","ar, cyb5a, fgf8a, foxa2, gata6, gli2a, nup107, pik3ca, pola1, polr3h, tmco1","INCREASED ADENOMAS PITUITARY"
"GO:0003707","6","0.281078424090807","0.206463244825363","18.75","ar, pparab, ppardb, raraa, roraa, rxraa","REDUCED MATURATION INDUCING STEROID RECEPTOR SIGNALLING OOCYTE"
"NUCLEAR RECEPTORS","6","0.281078424090807","0.206463244825363","11.54","ar, pparab, ppardb, raraa, roraa, rxraa","ACTIVATION HEPATIC NUCLEAR RECEPTORS"
"GO:0003714","4","0.284351030901888","0.370721537236612","20","ccnd1, hdac3, prmt5, raraa","STABILIZATION PPAR ALPHA CO-REPRESSOR"
"GO:0070330","2","0.285060058825011","0.0998388592690888","25","cyp1a, cyp1b1","REDUCTION IN OVARIAN GRANULOSA CELLS AROMATASE CYP19A1; INHIBITION AROMATASE; DECREASED AROMATASE CYP19A1 MRNA"
"G VEGF SIGNALING PATHWAY","4","0.289701959261666","0.382196613471421","19.05","cdc42, mapkapk2a, pik3ca, raf1b","REDUCED PRODUCTION VEGF"
"GO:1903409","5","0.2939354159387","0.0989862487326713","20","cyp1a, cyp1b1, roraa, sod1, tspo","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","40","0.30203003601484","0.0294059968430316","9.9","acat1, bub3, ccnd1, cdc42, cyb5a, cyb5r3, dldh, ephb2b, farsb, gata6, gli1, hmox1a, hsd17b10, krt94, mcm4, mthfd1b, myca, mycb, nhp2, pccb, pex19, pik3ca, raf1b, raraa, rbm8a, rpl15, rpl27, rpl31, rpl35a, RPS17, rps19, rps24, rps29, sdha, sdhb, srp72, stk11, tek, tnnt2a, umps","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"APOPTOSIS","5","0.309296848046483","0.268768585567721","8.93","apaf1, chuk, jun, myca, mycb","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"ABNORMALITY OF THE LIVER","25","0.311046587506165","0.0455964869915289","3.33","acadm, acat1, bmp2a, ccnd1, dldh, farsb, gale, gata6, hmox1a, hsd17b10, krt8, mcm4, myca, mycb, naga, nhp2, pccb, pex19, pik3ca, raf1b, rbm8a, sdha, sdhb, stk11, tnnt2a","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"GO:0019932","4","0.316030751668225","0.296682505490759","6.56","calcrla, gsk3b, nppa, ptger2a","INCREASED SECOND MESSENGER PRODUCTION"
"BLADDER CANCER","4","0.316727613829134","0.387837837449058","9.52","ccnd1, myca, mycb, raf1b","INCREASE CANCER"
"OXIDATIVE STRESS","3","0.322491838308175","0.177877289983816","12.5","cyp1a, hmox1a, sod1","PROPAGATION OXIDATIVE STRESS; N/A OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASED OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASE ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS; INCREASED ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS"
"GO:0030163","16","0.371890304687417","0.0713540108823773","10.46","bub3, cdc23, cul1a, gsk3b, hdac6, hsp90b1, nploc4, prp19, psmb3, psmb5, psmd6, psmd9, rnf7, sf3b3, ube2ia, wnt1","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"GO:0060291","2","0.374262532481393","0.261230233996605","14.29","ephb2b, gsk3b","DECREASED LONG-TERM POTENTIATION LTP"
"GO:1904019","3","0.374893273851898","0.191262855642504","13.64","hmox1a, krt8, tek","DECREASE APOPTOSIS OF CILIATED EPITHELIAL CELLS"
"INCREASED SUSCEPTIBILITY TO FRACTURES","5","0.385023364374141","0.267183299708454","14.29","ccnd1, fgf8a, nhp2, tpm3, wnt1","INCREASED DISEASE SUSCEPTIBILITY"
"GO:0001775","24","0.385311681537069","0.0447327464509329","12.24","apaf1, cdc42, cyb5r3, gli2a, hmox1a, impdh1b, jun, krt8, nppa, pa2g4b, pik3ca, pkma, prmt5, psmd6, ptpn6, raf1b, rap1b, raraa, roraa, rpl22, sart1, sod1, stk11, wnt1","ACTIVATION DENDRITIC CELLS"
"GO:0046562","5","0.404949666166141","0.282116002541017","18.52","adh5, akr1a1b, aldh9a1a.1, dldh, pkma","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"SMOOTH MUSCLE CELL PROLIFERATION","7","0.409109133101431","0.138043410657846","26.92","calcrla, ddx39b, hmox1a, igfbp5b, jun, ppardb, rps6kb1b","HYPERTROPHY/HYPERPLASIA SMOOTH MUSCLE"
"GO:0006629","33","0.434372997925269","0.031166446053319","16.02","acadm, acat1, adh5, bmp2a, cdc42, chpt1, crls1, cyb5r3, cyp1a, cyp1b1, dldh, eif6, fdx1, gata6, hdac3, hsd11b1la, hsd17b10, naga, pafah1b3, pccb, per2, pik3ca, pparab, ppardb, prkag1, prp19, ran, rdh10a, roraa, rxraa, sod1, tek, tspo","ALTERATION LIPID METABOLISM"
"ARYL HYDROCARBON RECEPTOR PATHWAY","3","0.439060235422614","0.1180880420974","6.25","cyp1a, cyp1b1, jun","UP REGULATION CYP1A1; ACTIVATION AHR"
"BREAST CANCER PATHWAY","11","0.450479094528923","0.110549638363517","9.65","ccnd1, fgf8a, gsk3b, jun, mre11a, myca, mycb, pik3ca, raf1b, rps6kb1b, wnt1","N/A BREAST CANCER"
"GO:0045333","8","0.456581094295548","0.13245592632649","11.11","cox6b1, cyp1a, dldh, ndufa5, ndufb5, pik3ca, sdha, sdhb","INCREASE OXIDATIVE METABOLISM"
"ENDOMETRIAL CANCER","6","0.461608461932854","0.204748830246901","8.82","ccnd1, gsk3b, myca, mycb, pik3ca, raf1b","INCREASE ENDOMETRIAL ADENOCARCINOMAS"
"GO:0050673","14","0.463171724445209","0.0789942164265002","17.07","ar, bmp2a, ccnd1, cdc42, gli1, hmox1a, id1, igfbp5b, jun, krt8, mycb, ppardb, stk11, tek","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GO:0004882","5","0.491821060475776","0.297332387844677","14.29","ar, ccnd1, jun, ncoa4, ran","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"UPPER MOTOR NEURON DYSFUNCTION","23","0.492107589722236","0.0468397184008924","4.85","acat1, cyb5a, cyb5r3, dldh, eif2b4, fgf8a, gli2a, hsd17b10, impdh1b, mre11a, naga, nars, nup107, pccb, pdhx, pex19, pik3ca, pola1, polr3b, roraa, sdha, sdhb, sod1","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"GO:0006281","12","0.504334323391933","0.0882876340757387","14.12","gtf2h4, lig3, mcm4, mre11a, nploc4, parp2, pola1, polr2i, polr2j, prp19, rpa3, ruvbl1","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","7","0.555123332483657","0.162751007320418","6.48","jun, myca, mycb, pik3ca, raf1b, rap1b, rps6kb1b","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"ESTROGEN RECEPTOR PATHWAY","4","0.574426958662758","0.0929227741892244","22.22","cyp1a, cyp1b1, jun, pparab","ACTIVATION ESTROGEN RECEPTOR"
"NRF2 PATHWAY","3","0.576488000627564","0.241903433820321","7.5","hmox1a, ppardb, rxraa","ACTIVATION NRF2"
"ABNORMAL OVARIAN MORPHOLOGY","7","0.602154651057552","0.163718123347426","18.92","cyb5a, fgf8a, nup107, pik3ca, polr3h, sdhb, stk11","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"SOMATIC MUTATION","7","0.612128306699026","0.1613073768917","8.33","ar, ccnd1, myca, mycb, pik3ca, raraa, stk11","INCREASED INDUCED MUTATIONS IN CRITICAL GENES; INCREASE MUTATIONS; INCREASE MUTATIONS IN CRITICAL GENES"
"GO:0050665","2","0.623055436118354","0.140287758219616","33.33","cyp1a, sod1","DECREASED HYDROGEN PEROXIDE PRODUCTION"
"GO:0007059","8","0.640748585516222","0.13529305468654","18.18","bub3, cdc23, cdc42, mre11a, ran, slc25a5, ube2ia, zw10","INCREASED CHROMOSOME MISSEGGREGATION"
"ELECTRON TRANSPORT CHAIN","12","0.648981572518926","0.0741487258838218","17.65","adh5, akr1a1b, ciapin1, cox6b1, cyb5a, cyp1a, dldh, fdx1, ndufa5, ndufb5, sdha, sdhb","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"GLOMERULAR SCLEROSIS","4","0.695312820189347","0.217464252090626","28.57","nup107, nup85, sdha, sdhb","DECREASED GLOMERULAR FILTRATION"
"G JAK STAT SIGNALING PATHWAY","5","0.703275984442646","0.167175202320896","31.25","ccnd1, myca, mycb, pik3ca, ptpn6","ACTIVATION JAK/STAT PATHWAY"
"GO:0007269","3","0.759187800465057","0.0999060774503065","12","gad2, gsk3b, rap1b","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"GO:0003824","10","0.804684098789321","0.0774065559488098","15.38","acat1, cth, gad2, impdh1b, mthfd1b, naga, nfs1, pkma, rrm1, umps","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"CYANOSIS","4","0.822094997400056","0.0527496988253603","21.05","cyb5a, cyb5r3, gata6, hsd17b10","N/A CYANOSIS OCCURS"
"PROSTAGLANDIN SYNTHESIS AND REGULATION","3","0.827937575300886","0.0559255462834223","11.54","ednraa, hsd11b1la, ptger2a","REDUCTION PROSTAGLANDIN E2 CONCENTRATION; REDUCED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"ABNORMALITY OF THE OVARY","11","0.911903632909059","0.0839791347192576","19.3","cyb5a, eif2b4, fgf8a, mre11a, myca, mycb, nup107, pik3ca, polr3h, sdhb, stk11","REDUCED PROSTAGLANDINS OVARY"
"NEOPLASM OF THE SKIN","3","0.964081255069491","0.0170689064993213","9.09","krt94, pik3ca, sdhb","SENSITISATION SKIN"
"HYPERTENSION ASSOCIATED WITH PHEOCHROMOCYTOMA","2","0.968451866382479","0.0325526913603011","28.57","sdha, sdhb","INCREASE HYPERTENSION"
"PSYCHOGENIC NON EPILEPTIC SEIZURE","2","0.968451866382479","0.0325526913603011","15.38","sdha, sdhb","OCCURRENCE EPILEPTIC SEIZURE"
"ABNORMALITY OF THE ENDOMETRIUM","2","0.977607156418226","0.035442164171512","18.18","pik3ca, sdhb","INCREASED HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASE HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASED ADENOSQUAMOUS CARCINOMAS OF ENDOMETRIUM"
"MALE REPRODUCTIVE SYSTEM NEOPLASM","4","0.995703261801534","0.135612403822333","26.67","ar, ephb2b, mre11a, stk11","MALFORMATION MALE REPRODUCTIVE TRACT; INDUCTION MALE REPRODUCTIVE TRACT; MALFORMED MALE REPRODUCTIVE TRACT"
"CTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP","2","1.19077048070672","0.0237155676016635","16.67","pparab, rxraa","UP REGULATION SREBF2"
"PARALYSIS","4","1.23722361533881","0.0528918925196304","17.39","pola1, sdha, sdhb, sod1","INDUCTION SOMATIC MUSCLE PARALYSIS; INDUCTION PHARYNGEAL MUSCLE PARALYSIS"
"FAS LIGAND FASL PATHWAY AND STRESS INDUCTION OF HEAT SHOCK PROTEINS HSP REGULATION","3","1.27028605160158","0.0829082266940842","11.54","apaf1, jun, mapkapk2a","ACTIVATION FAS; UP REGULATION FAS"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","3","1.31761192865467","0.0726020932650953","3.26","mcm4, pex19, pik3ca","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"CTOME SIGNALING BY EGFR","2","1.38829724496377","0.0722629899678249","25","cdc42, pik3ca","ACTIVATION EGFR"
"GO:0007009","2","1.39610604716583","0.107476602115966","22.22","ar, sod1","NARCOSIS"
"GO:0022414","3","1.42164402978875","0.110141989474403","8.33","ar, mre11a, tacr1b","INCREASED REPRODUCTIVE SUCCESS"
"NCRNAS INVOLVED IN WNT SIGNALING IN HEPATOCELLULAR CARCINOMA","6","1.42781707506351","0.0276488657884104","12.5","ccnd1, gsk3b, jun, myca, mycb, wnt1","INCREASE HERITABLE MUTATIONS IN OFFSPRING"
"JNK CASCADE","3","1.47858509902741","0.0388299333526837","13.64","cdc42, hdac3, nppa","ACTIVATION JNK"
"ABNORMAL CARDIAC TEST","2","1.49616522353042","0.0383606485480712","15.38","gata6, nppa","INCREASED CARDIAC ARRTHYMIA"
"GO:0006635","4","1.54860873207248","0.0206062305188696","20","acadm, acat1, pparab, ppardb","DECREASED PEROXISOMAL FATTY ACID BETA OXIDATION OF FATTY ACIDS; DECREASED MITOCHONDRIAL FATTY ACID BETA OXIDATION; DECREASED MITOCHONDRIAL FATTY ACID BETA-OXIDATION; INHIBITION MITOCHONDRIAL FATTY ACID BETA-OXIDATION"
"ABNORMAL LACTATE DEHYDROGENASE LEVEL","3","1.56578563521538","0.0228388837959709","33.33","acadm, myca, mycb","DOWN REGULATION GULCOSE-6-PHOSPHATE DEHYDROGENASE"
"DNA DAMAGE RESPONSE","5","1.6753929667758","0.0404289624600606","8.62","apaf1, ccnd1, mre11a, myca, mycb","INCREASED DNA DAMAGE-REPAIR"
"GO:0008152","2","1.78337319149391","0.0297481691596136","66.67","naga, rrm1","PRODUCTION CRITICAL METABOLITES CGA 330050 AND CGA 265307; METABOLISM OF AFB1 PRODUCTION OF REACTIVE ELECTROPHILES"
"GO:0015908","3","1.87300936485136","0.050026810836847","13.64","pparab, ppardb, rps6kb1b","INCREASED FA INFLUX"
"GO:1903009","4","1.91071526601729","0.0307350282409325","11.76","psmb3, psmb5, psmd6, psmd9","DECREASE GTPCH-1"
"CTOME CELLULAR RESPONSE TO HYPOXIA","4","1.91071526601729","0.0307350282409325","9.3","psmb3, psmb5, psmd6, psmd9","N/A HYPOXIA"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","4","1.9504701749977","0.0813939687369402","28.57","cyb5a, nup107, pik3ca, polr3h","INCREASED CIRCULATING ESTROGEN LEVELS"
"LEYDIG CELL DIFFERENTIATION","2","2.22750516007698","0.0359955833736477","66.67","ar, ccnd1","HYPERPLASIA LEYDIG CELL; INCREASE LEYDIG CELL TUMORS"
